Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction

Eur Heart J. 2015 Oct 7;36(38):2595-7. doi: 10.1093/eurheartj/ehv328. Epub 2015 Jul 28.

Authors

Adam Castaño¹, Sabahat Bokhari¹, Mathew S Maurer²

Affiliations

¹ Center for Advanced Cardiac Care, Division of Cardiology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
² Center for Advanced Cardiac Care, Division of Cardiology, Columbia University College of Physicians and Surgeons, New York, NY, USA msm10@columbia.edu.

PMID: 26224073
DOI: 10.1093/eurheartj/ehv328

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Amyloid Neuropathies, Familial / complications
Amyloid Neuropathies, Familial / diagnosis*
Heart Failure / etiology*
Humans
Stroke Volume / physiology

Supplementary concepts

Amyloidosis, Hereditary, Transthyretin-Related

Grants and funding

AG036778/AG/NIA NIH HHS/United States